Last updated: May 24, 2026
Brincidofovir (CMX001, an oral lipid conjugate of cidofovir) is supplied through a small number of contract manufacturing and sourcing channels supporting clinical and commercial development. Public data needed to name specific, current suppliers for drug substance (API) and finished dosage form is not available in the provided material.
H1: Brincidofovir suppliers for API and finished product: who manufactures CMX001
Who supplies brincidofovir (CMX001) drug substance (API) and finished dosage form?
Brincidofovir is developed and controlled as a specialized antiviral program, and supply chains are typically limited to development-era and contract manufacturing partners named in regulatory filings and commercial documentation.
API supply
- Public, supplier-specific naming for brincidofovir API is not provided in the input.
- Brincidofovir API procurement generally flows through program-defined manufacturing networks under sponsor control (or via authorized CMOs).
Finished product supply
- Finished dosage form manufacture for brincidofovir is likewise typically handled through sponsor-controlled CMOs.
- Supplier identity and current production status require mapping from FDA/EMA filings and commercial agreements, which is not included in the provided material.
Which companies manufacture CMX001 for clinical trials and commercial supply?
Brincidofovir program ownership and manufacturing responsibilities are sponsor-led, with CMOs engaged for scale synthesis and formulation.
- Clinical-trial manufacturing sites and contract manufacturers are normally referenced in:
- FDA Chemistry, Manufacturing, and Controls (CMC) submission histories
- Clinical trial protocols and investigator brochures
- NDA/MAA CMC sections
- Those documents are not present in the provided material, so supplier names cannot be extracted with accuracy.
What is the sourcing network for brincidofovir excipients, intermediates, and lipid conjugate chemistry?
Brincidofovir is a conjugated prodrug requiring:
- a cidofovir-derived core
- a lipid conjugate moiety
- specific stereochemical and purity controls
- formulation components for oral dosing
A supplier map for:
- intermediates
- lipid conjugate starting materials
- finishing excipients with suitable specs
- specialized analytical testing vendors
requires ingredient-level supplier disclosures that are not present in the provided material.
How does Brincidofovir commercial supply compare with other oral antivirals (e.g., brincidofovir vs. ganciclovir prodrugs)?
Comparative sourcing strategies are often similar across oral antiviral prodrugs:
- one or two qualified API synthesis routes
- limited formulation CMO support due to stability and assay sensitivity
- tight control of particle size, moisture, and impurity profile
A defensible company-by-company comparison requires supplier names and approval status for each program, which is not available in the provided material.
What does the FDA regulatory record imply about contract manufacturers for brincidofovir?
FDA regulatory records can indicate:
- manufacturing site locations
- CMC responsible parties
- postapproval changes
But supplier identification by company and site requires access to Orange Book-linked product records, FDA facility listings, and CMC supplements.
No regulatory listing content is included in the provided material.
What generic or biosimilar risk exists that could affect brincidofovir supplier availability?
Brincidofovir is a small-molecule antiviral prodrug; generic competition depends on:
- patent and exclusivity status
- ANDA availability
- CMC comparability requirements
A supplier-impact assessment requires current exclusivity and patent status plus ANDA/505(b)(2) filings, which is not included in the provided material.
What contract manufacturing/IP barriers limit alternative brincidofovir suppliers?
Typical barriers in complex prodrug programs include:
- proprietary synthesis steps and impurity control strategies
- validated analytical methods
- stability and formulation process know-how
- regulatory inspection history tied to specific facilities
A specific supplier barrier analysis requires the company and site record, which is not present.
Key Takeaways
- Brincidofovir (CMX001) supply is typically managed through sponsor-controlled CMO channels for both API and finished product.
- The provided material does not contain supplier-specific names or site-level manufacturing details, so supplier identification for brincidofovir cannot be stated as fact.
FAQs
- How do pharmaceutical sponsors source brincidofovir API for contract manufacturing?
- Which manufacturing facilities typically produce oral prodrug antivirals like brincidofovir?
- What documentation shows the contract manufacturers for a drug like CMX001?
- How do CMC transfers affect the availability of brincidofovir suppliers?
- Can ANDA filings change the number of brincidofovir suppliers in the market?
References
- No sources were provided in the input.
